Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Is BioLife Sciences (OTCPK: BLFE) An OTC Company Primed For Growth?

BioLife Sciences Inc

BioLife Sciences Inc. (BioLife), a commercialization accelerator, licensor and developer of technologies, has reportedly provided investors with a significant company update throughout the course of a two-year transformation. Over the course of the last two years, BioLife has gone through a number of changes evolving into a revamped corporate entity focused on disrupting various consumer verticals, with a specific focus on health and wellness. Let’s take a look at some of what the company has been up to over the last two years. BioLife Sciences is Born: In June of 2020, the OTC Markets public entity formerly known as Rhino Novi Inc. (RNOV) underwent a reverse merger transaction – changing its name and ticker symbol to BioLife Sciences Inc. (BLFE). While Rhino Novi originally focused on VOIP products, the newly formed BioLife would focus on developing and marketing disruptive technologies to a variety of consumer verticals. Harnessing the Antimicrobial Power of Copper? BioLife has reported it focused on the utilization of the natural antimicrobial power of copper and harnessing its innate benefits into everyday textiles. This dynamic elemental metal has a wide variety of beneficial traits, including being required by all plants and animals as a key mineral and nutrient necessary for survival. In the case of humans specifically, copper reportedly helps to boost red blood cell production, provides support to the immune system, and helps to keep nerve cells healthy. For plants, copper is a fundamental micronutrient that is a critical element of plant enzymes, it is essential for plants’ respiration, plays a key role in plant cell wall strength and contributes to the overall strength of the plant. More recently, copper has been shown to provide antimicrobial efficacy associated with copper alloy touch surfaces. Some hospital studies have shown copper’s effectiveness in lowering E.coli counts on brass doorknobs, as well as SARS-CoV-2, Rhinovirus Type 37, Rotavirus Strain WA, and Human Coronavirus 229E. BioLife says it has focused its attention on incorporating the power of copper into everyday products which are fabric-based and disruptive, in contrast to the market’s current offering. Some of these products in development include copper-infused fabric gardening pots, copper-infused gardening gloves, copper-infused microfiber towels and copper-infused air filters. What is MFusion? The company states that traditional copper-infused products that consumers will find on the market today provide limited-to-partial copper coverage. This means that there could are often gaps in the copper coverage, resulting in less-than-optimal results. BioLife addresses this problem with the introduction of their unique copper infusion process: MFusion. MFusion infuses copper into every sub-bundle of the fabric, providing more complete coverage. When copper is infused into textiles via MFusion, the resulting fabrics benefit from 100% evenly distributed copper coverage. MFusion can be applied to any textile – from t-shirts to air filters – with the result being total copper infusion. The 2022 Acquisition of Health Box LLC – What’s Next? In February of 2022, BioLife completed the acquisition of Health Box LLC – an Arizona-based orthomolecular medicine and natural health products company. By completing this acquisition - and appointing Nika Jaksic, Health Box’s founder, as the new COO, the company believes it has positioned itself to enter the orthomolecular and natural health products space. In order to facilitate the Company’s aggressive expansion plans, the Company filed for a Regulation A+ Tier 1 Offering. The SEC qualified BioLife and the Company is eligible to raise up to $20 million. If successful in its capital raise, BioLife states that they intend to pursue rapid expansion of its existing and contemplated product offerings, audits, and the potential of filling towards uplisting to the OTC Venture Market (OTCQB). This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Contact Details BioLife Sciences ir@biolifesciences.com Company Website https://www.biolifesciences.com

August 16, 2022 01:25 PM Eastern Daylight Time

NextFerm Technologies announces a $3 million Supply agreement for its vegan protein: ProteVin™

NextFerm Technologies Ltd.

A 4.5 years supply agreement with Spacemilk, an American health and sports nutrition brand Currently, the company has a base of potential customers, including global food, dietary supplement companies and international brands, who are examining the integration of ProteVin™ in a variety of alternative products (Yokneam Illit, August 8, 2022) – NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, fermentation-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced today that it has entered into a 4.5 years supply agreement totaling approximately $3 million with Spacemilk., an American vegan health and sports nutrition brand. This agreement includes the initial supply of protein in the amount of few tons carried out in June 2022. As reported to the company, Spacemilk is expected to launch in the fourth quarter of 2022 and for the first time in the U.S., a vegan sports nutrition protein powder based on ProteVin™. The agreement stipulates that Spacemilk will promote the ProteVin™ brand on the product packaging, as it is the dominant nutritional component underlying the product. The agreement includes a mutual commitment to purchase and supply ProteVin™ totaling approximately $1.6 million from July 2022 until the end of June 2025, and an estimation of an additional purchases of $1.4 million by the end of 2026. It should be noted that until the expected operation of the expanded production facility in 2023, the Company will supply protein in the amount of few tons.The company is making progress in its strategic plan and in achieving the other goals it set for itself for 2022, including: Generating demands and receiving additional purchase orders. The company presents the product at exhibitions of raw materials for food and dietary supplements in the US, Europe and Asia and accelerates launching efforts. Currently, the company has a base of potential customers, including global food, dietary supplement companies that are in various stages of evaluating ProteVin™ and integrating it into a variety of vegan products. Expanding ProteVin's production capacity from an initial capacity of tens of tons per year, to a scale of hundreds of tons per year in 2023 which expected to begin during the second half of 2022. Boaz Noy, Chief Executive Officer of NextFerm, said: "We are pleased to announce the first multi-year supply agreement for ProteVin™. This is an important step towards realizing the company's vision of positioning ProteVin™ as a leading vegan protein in the thriving global alternative protein industry. ProteVin™ is gaining a lot of interest from global food and dietary supplement companies and is currently being tested by dozens of potential customers. This customer base continues to grow and is expected to yield the company the following agreements. At the same time, we are preparing to increase production capacity to a scale of hundreds of tons in 2023, to meet the demand." Walter Ross, Chief Executive Officer and Founder of Spacemilk, said: "Based on my background and experience in sports nutrition - as a business owner, personal trainer, and consumer in the industry, I can say that ProteVin™ is everyone’s perfect protein. ProteVin’s unique qualities provide amino acid content like whey, ethics and sustainability superior to plant proteins, and a flavor profile that’s better than both. My company, Spacemilk, only sources the highest quality, cleanest, and most sustainable and effective ingredients, which made developing our flagship product with ProteVin™ an easy choice. We’re excited to take ProteVin™ and be first to market with a new category of protein powder, which we believe will replace large sections of the plant and animal nutrition industry today." About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

August 16, 2022 11:09 AM Eastern Daylight Time

Code 1 Supply Named as Exclusive Distributor for XDcuff® Patient Restraint System

Code 1 Supply

Code 1 Supply, the leading distributor of best-in-class medical diagnostics and brand-name supplies, has been named as the exclusive distributor of XDcuff®, a stretcher-integrated limb restraint system for emergency medical service providers. XDcuff is a patented clip-in or secure-in reusable limb restraint system that greatly reduces the risk of patient injury by decreasing the amount of time EMS providers spend with uncooperative patients. The system allows medics to quickly anchor limb restraints, without confusion or special knots to be formed. The product has been perfected after several years of development and made by the people who use them – paramedics. “We are honored to partner with XDcuff exclusively to offer their innovative patient restraint system to new and existing Code 1 Supply clients,” said Matt Regan, CEO at Code 1 Supply. “I have experienced firsthand the need for a more robust patient restraint system that allows paramedics to quickly and easily restrain a patient that is a risk to themselves or to others during transit. XDcuff provides the security that EMS providers are looking for, and I look forward to working directly with EMS teams nationwide to offer XDcuff on their ambulances.” Working in collaboration, Code 1 Supply and XDcuff will be attending EMS-focused events in the coming months in order to demonstrate the ease of use and importance of the XDcuff patient restraint system for EMS teams. Team members from both companies will be at EMS World Expo October 12-14 in Orlando, FL (Booth #1204) and at EMS Pro Expo & Conference at Foxwoods Casino in Connecticut October 26-29 (booth #528), where attendees can learn more about XDcuff and other product offerings from Code 1 Supply. “Our team at XDcuff looks forward to working exclusively with Code 1 Supply to bring our patient restraint system to EMS teams nationwide,” said David Dufek, CEO at XDcuff. “As a paramedic myself, I know the importance of safe patient transport for both patient and EMS provider. Working with Code 1 Supply, another paramedic-owned company, I know we will be able to make a great impact on efficiencies within the ambulance while ensuring safe transport of confused or agitated patients.” Representing the most trusted and respected manufacturers of medical diagnostics, supplies and equipment, Code 1 Supply offers next-day shipping for all orders and free shipping on orders over $750. The XDcuff patient restraint system is now available exclusively through Code 1 Supply. To learn more about how the company can support your patient restraint needs, please visit https://www.code1supply.com/. About Code 1 Supply Code 1 Supply is an international distributor of best-in-class medical diagnostics, brand-name supplies, and equipment, and a leading provider of CPR training equipment and student materials. Representing the most trusted and respected manufacturers of medical diagnostics, supplies and equipment, Code 1 Supply is committed to providing innovative products and outstanding services at the best prices. We are proud to be the medical supply partner for healthcare providers, hospitals, urgent care centers, businesses and communities worldwide. For more information, visit www.code1supply.com. About XDcuff® XDcuff® Clip-In or Secure-In Reusable Limb Restraints greatly reduce the risk of injury by simply reducing the amount of time EMS providers spend with uncooperative patients. Improve treatment and on-scene times when treating confused and agitated patients. Using a standard application plan helps eliminate any confusion on how or where to anchor restraints. Improve safety without the high cost. We developed XDcuff out of necessity and offer our system at a competitive price. Our innovative design change pre-connects the anchors (clips) to the stretcher for fast access and deployment in these emergencies. No more time wasted searching, looping, or tying special quick release knots. Eliminating these steps has proven to greatly reduce restraint times providing for a much safer and more effective work environment. Visit https://www.xdcuff.com/ for more information. Contact Details Rita Murphy +1 774-454-1516 rita.murphy@svmpr.com Company Website https://www.code1supply.com/

August 16, 2022 10:00 AM Eastern Daylight Time

Don’t Give This Company The Brush Off? Brüush Offers Mid-Priced Electric Toothbrush In An Interesting Market

Bruush Oral Care Inc.

While the jury’s still out on whether electric toothbrushes are more effective than manual ones, a number of companies are betting consumers will increasingly adopt them. https://profiles.smallcapsdaily.com/bruush/ The American Dental Association says both manual and electric brushes remove plaque and bacteria from teeth — so long as you’re using a proper brushing technique. More recently, the Journal of the American Dental Association published a survey that found that 13,000 out of 16,000 patients who used an electric toothbrush reported better oral health. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. Some are betting big with high-priced devices, while others are banking on consumers looking for value. And then there are those that fall somewhere in the middle. Koninklijke Philips N.V.’ s (NYSE: PHG) Sonicare line has a variety of options, with the least expensive starting at about $20 and the company’s most advanced electric toothbrush — which gets guidance from an app using artificial intelligence — selling for $380. Joining Philips with a lower-end offering is Quip. Starter kits for Quip’s adult electric toothbrushes start at $20. You get the handle with three-month battery life, a soft-bristle brush head and a cover. Quip will send you a new brush head and free battery every three months for $5. Brushing Off The Competition? Then there’s Brüush (NASDAQ: BRSH), which says it takes the confusion out of deciding what to buy with its $79 electric toothbrush kit. Brüush, which comes in three core colors and the seasonal colors, has six cleaning modes for every type of brusher. The company’s website says Gentle makes smiles clean and bright, while the Tongue mode keeps your mouth smelling fresh. Brüush estimates 70% of its customer base is between ages 18 and 45 years old, a group that’s under-penetrated compared to baby boomers in terms of using an electric toothbrush. This age group also consists of the first digital generations when it comes to shopping and e-commerce brand loyalty to businesses like Apple Inc. (AAPL), perhaps a positive for a company where the website accounts for the majority of sales. If you’re in the market for an electric toothbrush, Brüush says to be sure to buy one that comfortably fits inside your mouth — usually, smaller is better so you can maneuver it to make sure you’re brushing all your teeth. Looking for a brush with soft bristles that are gentle on teeth and gums to avoid irritation is a good idea — a self-timer feature also is recommended to ensure you brush the full two minutes dentists recommend. Toothbrush heads should be replaced every 12 weeks — which makes Brüush’s subscription model that sends customers three new brush heads for $18 every six months a convenient way to stay on top of changing them. By comparison, replacing brush heads for Sonicare products can cost as much as $43 for a three-pack, and the price of the Procter & Gamble Co. (NYSE: PG) Oral-B line of replacement brush heads reaches as high as $40 for a three-pack. Visit Brüush’s website to learn more about the company and its products. About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR - Colette Eymontt colette@tradigitalir.com Company Website http://www.tradigitalir.com

August 16, 2022 08:56 AM Eastern Daylight Time

AngelEye Health Named to Prestigious Inc. 5000 Listing

AngelEye Health

AngelEye Health, a leading provider of family engagement solutions for hospital neonatal and pediatric intensive care units, today announced that the organization was named 3,412 (and 195 in Health Services) on the annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. The list represents a one-of-a-kind look at the most successful companies within the economy’s most dynamic segment—its independent businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000. AngelEye has nearly a decade of experience in patient and family engagement in pediatric and neonatal intensive care environments. The company’s proven HIPAA-compliant family engagement platform integrates parents simply and seamlessly into the child’s care. In the past three years alone, the company has grown exponentially, more than tripling its annual revenue, growing its employee base to 39, a 5x increase since 2018, and expanding its extensive client list to 125+ partners across the U.S. with a 100% retention rate. “We are honored to be ranked on such an esteemed list of enterprises, which includes many of the nation’s most recognized companies,” said Christopher Rand, CEO at AngelEye Health. “Our AngelEye Health team is committed to our mission to improve family engagement in the hospital by easing workflow challenges for staff and improving the experience for families. This ranking is a testament to our hard work and our steadfast dedication to continuous innovation and support of our partner hospitals.” Addressing bonding, patient progress and treatment communication, feeding, and focused education, AngelEye offers a portfolio of solutions for supporting the highly specialized needs of the neonatal environment. 31,246 families signed up for AngelEye Health services in 2021, leveraging the company’s advanced engagement technologies to view hospitalized infants more than 7 million times for almost 303,000 hours of connection along with receiving patient updates via more than 56,000 text, photo, and video messages from hospital staff. “The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.” AngelEye was designed by clinicians to improve the efficiency of critical care workflows, resulting in improved communication and collaboration between families and care teams. The innovative system delivers on the promise of family-centered care, offering advanced camera technology with live-streaming video, a PatientConnect app that allows clinicians to send text, photos, and recorded video, an OnlineEducation portal to empower parents and ensure a timely and successful transition home, and a MilkTracker app that makes the feeding process safer, efficient, and engaging for providers and families. About Inc. The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference & Gala is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit www.inc.com. For more information on the Inc. 5000 Conference & Gala, visit http://conference.inc.com/. About AngelEye Health AngelEye Health has a deep understanding of the value that both family engagement and family-centered care bring to the neonatal and pediatric intensive care environment. We provide a complete HIPAA-compliant tele-engagement platform to integrate parents simply and seamlessly into the child's care team. Our approach has a proven, positive impact on the quality of the family experience, care delivery workflows for the dedicated bedside team, and patient outcomes. From admission to discharge, AngelEye positively impacts staff, families, and patients along the journey and ultimately to a successful transition home. From bonding, patient progress and treatment communication, feeding, and focused education, AngelEye offers a portfolio of solutions for supporting the highly specialized needs of the NICU and PICU today and of the future. www.angeleyehealth.com Contact Details Jessy Green +1 917-689-9295 jessy.green@svmpr.com Company Website https://www.angeleyehealth.com/

August 16, 2022 07:00 AM Eastern Daylight Time

Nasal-spraying LiveSpo NAVAX: Probiotics of the next generation for respiratory infections

LiveSpo

HANOI, VIETNAM - Media OutReach - 15 August 2022 - On July 20 nd, the Scientific Reports journal (the Nature) officially annouced a break-through research on using LiveSpo NAVAX probiotic spores in nasal spray form to support the treatment of acute respiratory infections in children infected with respiratory syncytial virus (RSV) [1] Respiratory syncytial virus (RSV) is a leading cause of Acute Respiratory Tract Infections (ARTIs) in young children. The World Health Organization estimates that 48,000-74,000 children - younger than five years old die yearly due to RSV infection. Up to now, there is no available vaccine and specific treatment for RSV-infected children. Researchers at Vietnam National Children’s Hospital conducted the first clinical trial in infected children with Respiratory Syncytial Virus (RSV). They demonstrated the safety and beneficial effects of a nasal-spraying liquid suspension of Bacillus spore probiotics (LiveSpo® NAVAX) in the supportive treatment of ARTIs. The research team published results showing that the nasal-spraying LiveSpo NAVAX) reduced the load of RSV and influenza virus by 300-fold and 1000-fold, and was 50- to 70-fold more effective than physiological saline after 2-3 days of treatment. Semi-quantitative real-time PCR results of co-infection bacteria on day three of treatment show that patients in the NAVAX) group (spraying probiotics spores) were negative while patients in the control group (not using probiotic spores) only had a slight decrease in bacterial co-infection concentration. The team also assessed that the nasal-spraying Bacillus spores could rapidly and effectively relieve symptoms of RSV-induced ARTIs while exhibiting a strong effect in reducing viral load and inflammation. Nasal-spraying probiotics may provide the basis for simple, low-cost, and effective symptomatic adjuvant treatment against viral infections. Dr. Nguyen Hoa Anh - Director of Sporebiotics Research Center said: “The interaction mechanism between LiveSpo NAVAX) 's Bacillus spores and the virus and the nasal mucosal immune system is based on nonspecific binding suggesting that LiveSpo Navax may be helpful against viral variants that cause respiratory diseases or other rapidly emerging respiratory viruses such as influenza virus or coronavirus. The research is a breakthrough scientific achievement, contributing to enhancing the image of Vietnam in the field of science in the international arena and making a great contribution to public health care, especially for children. [1] Scientific Report (July 20th, 2022). “Nasal‑spraying Bacillus spores as an efective symptomatic treatment for children with acute respiratory syncytial virus infection” https://www.nature.com/articles/s41598-022-16136-z.pdf About LiveSpo LiveSpo® NAVAX containing more than 5-billion spores of beneficial bacteria Bacillus subtilis and Bacillus clausii, and 0.9% physiological saline up to 5mL.The product supports to help clean ears, nose, throat; and prevent, reduce the risk of ear, nose, throat infections, and increase beneficial bacteria, protect and the nasal mucosa. Company Website https://livespo.com/en/ Contact Details Media Contact huong.md@livespo.com Company Website https://livespo.com/en/

August 15, 2022 11:43 AM Eastern Daylight Time

Image

Elsevier gives free access to content and resources via just-launched Monkeypox Information Center to accelerate fight against viral disease

Elsevier

For the benefit of healthcare professionals, medical researchers, and the public, Elsevier, a leading scientific publisher and global information analytics business specializing in science and health, has today launched a Monkeypox Information Center. The hub will be continually updated and provide free access to relevant research and clinical information on the Monkeypox virus from across Elsevier’s scientific and medical journals and clinical resources for healthcare professionals. This research and health information will be freely available from Elsevier platforms and shared with the World Health Organization (WHO). In addition, the company, will contribute Monkeypox-relevant journal articles to PubMed Central, the archive of biomedical and life sciences research at the U.S. National Institutes of Health’s National Library of Medicine, for as long as the Monkeypox public health emergency is ongoing. Updated frequently, The Monkeypox Information Center will offer access to journal articles and book chapters to ensure researchers, clinicians and the public can readily discover relevant content from the rapidly growing body of literature. It will also provide a machine-readable corpus to enable use of text and data mining technologies to identify patterns and relationships in data, as countries around the world address this global public health crisis. The Monkeypox Information Center is updated continuously with the latest research information on the virus and the disease. In addition, Monkeypox-related journal articles and book chapters are made freely available on ScienceDirect, Elsevier’s global platform of peer-reviewed scholarly literature. Around 400 journal articles were identified initially, and latest research and guidance will be added as they become available. The launch of this information center is part of Elsevier’s commitment to support the research and healthcare communities in their efforts to address public health emergencies and follows the company’s information hubs for Ebola, SARS, Zika and MERS outbreaks, and the current pandemic response continues to be supported by the existing novel coronavirus resource centre. “The Monkeypox Information Center will support healthcare professionals, clinical researchers, and policy makers in understanding Monkeypox, so that best efforts can be made towards its prevention and treatment,” said Kumsal Bayazit, CEO, Elsevier. “To support research and healthcare communities we serve, with the public health emergency, we are providing an information center where the medical community, patients, and their caregivers can readily access the most up-to-date information.” The Monkeypox Information Center is hosted on Elsevier Connect, the company’s public news and information website. It allows free access to content curated in consultation with Elsevier clinicians and other experts. It brings together content from the company’s journals, books, monographs and clinical information solutions as well as resources from other information providers and major health and government organizations. Also available is information typically used by practicing nurses and physicians, plus resources designed specifically for patients and their families. The site also links to other authoritative resources, including the WHO and the U.S. Centers for Disease Control and Prevention. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals’ advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ digitized journals, including The Lancet and Cell; our 43,000+ eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com. Contact Details Elsevier Andrew Davis +44 7393 242466 andrew.davis@elsevier.com Elsevier Communications, US Dan DiPietro-James +1 773-251-8744 dan.james@elsevier.com Company Website https://www.elsevier.com/

August 15, 2022 04:00 AM Eastern Daylight Time

This Electric Toothbrush Has 6 Cleaning Modes For Reportedly Brighter Smiles

Bruush Oral Care Inc.

https://profiles.smallcapsdaily.com/bruush/ Toothbrushes have come a long way since Babylonians and Egyptians started brushing their teeth with frayed twigs around 3000 BCE. The first more modern toothbrush with a handle carved from cattle bone and a brush made from swine bristles was produced in England around 1780. Natural bristles were used until DuPont de Nemours Inc. (NYSE: DD) invented nylon, which started the development of the truly modern toothbrush in 1938 and the first electric toothbrush in 1939. Although electric toothbrushes date back more than 80 years, they have seemingly not achieved widespread adoption. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. Electric toothbrushes clean teeth, gums and tongue by using rotation or side-by-side movement of the head. Electric toothbrushes are an effective way to remove plaque and reduce gingivitis, and studies show they are more thorough at cleaning teeth than traditional manual toothbrushes. But the moderate adoption rate of the devices arguably demonstrates that consumers need to be educated and provided compelling value propositions to buy them. Cost is a major constraint to the market, and people don’t see them as an attractive addition to their bathroom countertops. Better Brushing? Enter Brüush (NASDAQ: BRSH). While most electric toothbrushes provide 500 strokes per minute, Brüush says its model provides up to 31,000 strokes per minute, attacking plaque 100 times more vigorously than a manual toothbrush. Brüush has six cleaning modes for every type of brusher. The Brüush lithium-ion battery is built to last four weeks on a single charge, and the compact magnetic case makes traveling with the device convenient. The Brüush toothbrush, which comes in five colors with three brush heads and a USB power adapter and charger, retails for $79. And if you sign up for a subscription, Brüush will send you three new brush heads every six months for $18 — that’s just $6 per brush head. Replacing brush heads for Koninklijke Philips N.V.’s (NYSE: PHG) Sonicare can cost as much as $43 for a three-pack, and the price of Procter & Gamble Co. (NYSE: PG) Oral-B line of brush heads reaches as high as $40 for a three-pack, depending on the model. Brüush estimates that 70% of its customer base is between ages 18 and 45 years old, a group that’s under-penetrated compared to baby boomers in terms of using an electric toothbrush. This age group also consists of the first digital generation when it comes to shopping, possibly a positive for a company where its website accounts for the majority of sales. Visit Brüush’s website to learn more about the company and its products. About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR Colette Eymontt colette@tradigitalir.com Company Website https://www.bruush.com

August 11, 2022 01:41 PM Eastern Daylight Time

This Electric Toothbrush Has 6 Cleaning Modes For Reportedly Brighter Smiles

Benzinga

Toothbrushes have come a long way since Babylonians and Egyptians started brushing their teeth with frayed twigs around 3000 BCE. The first more modern toothbrush with a handle carved from cattle bone and a brush made from swine bristles was produced in England around 1780. Natural bristles were used until DuPont de Nemours Inc. (NYSE: DD) invented nylon, which started the development of the truly modern toothbrush in 1938 and the first electric toothbrush in 1939. Although electric toothbrushes date back more than 80 years, they have seemingly not achieved widespread adoption. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. Electric toothbrushes clean teeth, gums and tongue by using rotation or side-by-side movement of the head. Electric toothbrushes are an effective way to remove plaque and reduce gingivitis, and studies show they are more thorough at cleaning teeth than traditional manual toothbrushes. But the moderate adoption rate of the devices arguably demonstrates that consumers need to be educated and provided compelling value propositions to buy them. Cost is a major constraint to the market, and people don’t see them as an attractive addition to their bathroom countertops. Better Brushing? Enter Brüush (NASDAQ: BRSH). While most electric toothbrushes provide 500 strokes per minute, Brüush says its model provides up to 31,000 strokes per minute, attacking plaque 100 times more vigorously than a manual toothbrush. Brüush has six cleaning modes for every type of brusher. The Brüush lithium-ion battery is built to last four weeks on a single charge, and the compact magnetic case makes traveling with the device convenient. The Brüush toothbrush, which comes in five colors with three brush heads and a USB power adapter and charger, retails for $79. And if you sign up for a subscription, Brüush will send you three new brush heads every six months for $18 — that’s just $6 per brush head. Replacing brush heads for Koninklijke Philips N.V.’ s (NYSE: PHG) Sonicare can cost as much as $43 for a three-pack, and the price of Procter & Gamble Co. (NYSE: PG) Oral-B line of brush heads reaches as high as $40 for a three-pack, depending on the model. Brüush estimates that 70% of its customer base is between ages 18 and 45 years old, a group that’s under-penetrated compared to baby boomers in terms of using an electric toothbrush. This age group also consists of the first digital generation when it comes to shopping, possibly a positive for a company where its website accounts for the majority of sales. Visit Brüush’s website to learn more about the company and its products. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 11, 2022 09:52 AM Eastern Daylight Time

1 ... 185 186 187 188 189 ... 281

Back